Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Short Interest Update

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) was the target of a large increase in short interest during the month of June. As of June 15th, there was short interest totaling 54,009 shares, an increase of 486.0% from the May 31st total of 9,216 shares. Based on an average daily volume of 148,319 shares, the short-interest ratio is presently 0.4 days. Currently, 1.0% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ATHE. Zacks Research upgraded Alterity Therapeutics to a “hold” rating in a research note on Wednesday, June 17th. LADENBURG THALM/SH SH began coverage on Alterity Therapeutics in a research report on Tuesday, June 16th. They set a “buy” rating and a $10.00 price objective on the stock. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Alterity Therapeutics in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $10.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Alterity Therapeutics stock. Citadel Advisors LLC purchased a new stake in shares of Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 22,144 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned about 0.25% of Alterity Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 2.14% of the company’s stock.

Alterity Therapeutics Price Performance

NASDAQ ATHE opened at $4.92 on Friday. The business’s fifty day moving average price is $4.42 and its 200-day moving average price is $3.74. Alterity Therapeutics has a 1-year low of $4.14 and a 1-year high of $350.00.

About Alterity Therapeutics

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.